Pesticide and Environmental Update
Helping
Beekeepers Beat American Foulbrood
American foulbrood (AFB)—caused by the spore-forming bacterium
Paenibacillus larvae—is the most serious infectious disease of honey
bees. Infected bee colonies must be burned, and that is costly for
beekeepers.
Since the 1950s, the only treatment approved for use in the United
States to prevent AFB has been the antibiotic oxytetracycline (OTC), sold
under the brand name “Terramycin.” But there have been several reports
over the past few years of loss of effectiveness of OTC.
Dan Murray, a molecular biologist in the ARS Honey Bee Research Unit at
Weslaco, Texas, has figured out why, after so many years, the AFB
bacterium has suddenly developed resistance to OTC. Murray, assisted by
ARS molecular biologist Katherine Aronstein, discovered in P. larvae a
natural plasmid—dubbed “pMA67”—that contains an OTC resistance
gene. Plasmids are small DNA molecules containing up to several dozen
genes that bacteria pass on when they reproduce.
This is the first report of any tetracycline resistance gene being
found in any Paenibacillus bacteria.
Among 35 P. larvae strains tested from across the United States and 1
from Canada, all 21 OTC-resistant strains possessed this plasmid and all
15 OTC-sensitive strains did not.
“This finding was unexpected,” says Murray. “Other scientists
have found plasmids in various AFB bacterial strains, but none of them
conferred antibiotic resistance. This plasmid is significant because it
has rendered useless what until very recently has been the only effective
preventive treatment for AFB.”
Fortunately, ARS scientists at Beltsville, Maryland, have recently
shepherded approval by the Food and Drug Administration of a new
antibiotic against AFB called “tylosin.”
There are two likely reasons for the relatively rapid spread of OTC
resistance: First, bees from broad geographical areas are brought together
when beekeepers rent out their hives to agricultural producers for
pollination. That means the bees can spread OTC-resistant bacteria to bees
they wouldn’t normally encounter. Second, based on its DNA sequence,
plasmid pMA67 is thought to have the ability to transfer to other
bacterial cells in a process called “plasmid mobilization.” This means
that, in addition to passing the plasmid—and its OTC resistance genes—on
to their descendants, bacteria can physically transfer a copy of the
plasmid to other bacterial cells they come in contact with. It is the same
phenomenon largely responsible for spread of antibiotic resistance among
disease-causing bacteria in humans. OTC resistance in P. larvae presumably
began when, at some point, pMA67 was transferred from some other bacterial
species into P. larvae.
“This is strong evidence for a mechanism behind OTC resistance in an
important honey bee pest,” says Jay D. Evans, an ARS researcher at the
Bee Research Laboratory in Beltsville, Maryland. “OTC resistance has
arisen in many treated populations, and it will be interesting to explore
the role played by this plasmid—and possibly others—in generating
resistance.”
Antibiotic-resistant strains can be detected in the laboratory with
standard microbiological procedures and assays. This discovery resulted in
a DNA-based method of detecting antibiotic-resistant P. larvae and may
also lead to better strategies for combating other infectious agents of
honey bees.—By Alfredo Flores, Agricultural Research Service Information
Staff.
|